Q-omics provides the consensus-scored RN7SL116P profile across patient tissues and cancer cell-line models. RN7SL116P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RN7SL116P is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, RN7SL116P RNA expression shows 12,730 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, UCEC, and LSCC as cancer lineages where RN7SL116P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL116P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL116P survival associations across molecular data types. RN7SL116P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL116P RNA expression–survival associations across cancer types. High RN7SL116P expression shows unfavorable associations in LUAD, OV, KICH, LIHC and KIRC, but favorable associations in ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .031). Together, the overview and detailed table identify LUAD as the clearest survival context for RN7SL116P RNA expression.
This table summarizes RN7SL116P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL116P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL116P shows lower tumor expression in LUSC and ESCA and higher tumor expression in UCEC and LUAD. The UCEC box plot shows higher RN7SL116P RNA expression in tumor versus normal tissue (log2 FC = +1.165, t-test p = .048).
This table shows molecular features associated with RN7SL116P in patient tissues and cancer cell lines. In patient samples, RN7SL116P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
